Skip to main content

Table 1 Selected migraine drug development programs (compiled from

From: Migraine pathogenesis and state of pharmacological treatment options

Drug Mechanism of action Stage of development
Acute attack
Telcagepant (MK-0974) CGRP receptor antagonist Phase III- complete
BI 44370 CGRP receptor antagonist Phase II
COL-144 5-HT1F receptor agonists Phase II
SB-705498 TRPV1 receptor antagonists Phase II
BGG492 AMPA receptor antagonist Phase II
Tezampanel (LY-293558) AMPA and kainate receptor antagonist Phase II
LY466195 GLUK5 kainate receptor antagonists Phase II
NPS 1776 Anticonvulsant Phase II
BGC20-1531 Prostanoid EP4 receptor antagonist Phase II
NXN-188 nNOS inhibition and 5-HT1B/D agonist Phase II
Ramelteon Melatonin MT1 and MT2 receptor agonist Phase IV
Botulinum Toxin type A Unknown Phase III
Tonabersat Gap junction/CSD inhibitor Phase II- failed in migraine without aura
ADX10059 mGluR5 Modulator Phase II
Perampanel (E2007) AMPA receptor antagonist Phase II
GW274150 iNOS Phase II- failed
Carisbamate (RWJ-333369) Anticonvulsant Phase II- failed
  1. CGRP, calcitonin gene-related peptide; CSD, cortical spreading depression; nNOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase